XTX Topco’s ADMA Biologics ADMA Stock Holding History

XTX Topco’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Sell	141,309 -411,484	-74%	-$3.75M	0.02%	1635
2026 Q1	$4.98M	Buy	+552,793	New	+$8.72M	0.09%	284
2025 Q4	–	Sell	-86,503	Closed	-$1.27M	–	3266
2025 Q3	$1.27M	Buy	+86,503	New	+$1.48M	0.07%	432
2025 Q2	–	Sell	-12,073	Closed	-$240K	–	2287
2025 Q1	$240K	Sell	12,073 -11,034	-48%	-$191K	0.01%	1575
2024 Q4	$396K	Buy	+23,107	New	+$435K	0.03%	968
2024 Q2	–	Sell	-106,841	Closed	-$705K	–	1803
2024 Q1	$705K	Sell	106,841 -62,232	-37%	-$340K	0.1%	292
2023 Q4	$764K	Buy	169,073 +120,052	+245%	+$444K	0.17%	79
2023 Q3	$175K	Buy	49,021 +37,423	+323%	+$144K	0.03%	1058
2023 Q2	$42.8K	Sell	11,598 -94,398	-89%	-$350K	0.01%	1258
2023 Q1	$351K	Buy	105,996 +95,372	+898%	+$330K	0.07%	531
2022 Q4	$41.2K	Sell	10,624 -10,704	-50%	-$33K	0.01%	1052
2022 Q3	$52K	Buy	+21,328	New	+$51.2K	0.01%	1019
2021 Q4	–	Sell	-17,709	Closed	-$20K	–	648
2021 Q3	$20K	Sell	17,709 -7,172	-29%	-$10K	0.01%	640
2021 Q2	$40K	Buy	+24,881	New	+$43.8K	0.01%	740

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

XTX Topco's ADMA Position: Q2 2026 in Review

XTX Topco reduced its ADMA Biologics (ADMA) stake by 74% in Q2 2026, selling an estimated $3.75M and leaving 141,309 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #1635.

XTX Topco first reported a position in ADMA in Q2 2021 and has held it in 14 quarters since. The position peaked at $4.98M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

XTX Topco held 141,309 shares of ADMA Biologics worth $1.18M as of Q2 2026.
XTX Topco sold 411,484 ADMA Biologics shares in Q2 2026, an estimated $3.75M.
ADMA Biologics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1635 holding.
XTX Topco first reported a position in ADMA Biologics in Q2 2021 and has held it in 14 quarters since.
XTX Topco's ADMA Biologics position peaked at $4.98M in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.